Kunming Longjin Pharmaceutical Co., Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 254.026 million compared to CNY 275.292 million a year ago. Operating income was CNY 8.643 million compared to operating loss of CNY 21.954 million a year ago. Net income was CNY 11.811 million compared to net loss of CNY 23.107 million a year ago. Basic earnings per share from continuing operations was CNY 0.0295 compared to basic loss per share from continuing operations of CNY 0.0577 a year ago.